NCT06697535View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

July 30, 2026

Conditions
Neuromyelitis Optica Spectrum Disorders
Interventions
DRUG

JYP0061

Administered orally with a dose reduction over time as specified in Arm descriptions. Tablets are taken within a specific time frame after meals.

DRUG

Intravenous Glucocorticoids

Administered intravenously with a gradually decreasing dose over time, as specified in the Standard Dose Glucocorticoids arm.

DRUG

Oral Glucocorticoids

Administered orally with a tapered dosing schedule, as specified in the Standard Dose Glucocorticoids arm, with adjustments based on participant response.

Trial Locations (1)

410008

RECRUITING

Xiangya Hospital，Central South University, Changsha

All Listed Sponsors
lead

Guangzhou JOYO Pharma Co., Ltd

INDUSTRY